Bimzelx
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
UCB presentation highlights impacts of epilepsy on daily life
The data underlines the consequences of disrupted sleep for patients and caregivers
UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency
TK2d is an extremely rare disease characterised by severe and progressive muscle weakness
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
InflaRx reports positive phase 2 results for HS and CSU treatments
Topline results demonstrated treatment efficacy for both conditions
UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome
The study demonstrated a sustained reduction in seizures for patients
UCB shares promising results for fenfluramine in ultra-rare form of epilepsy
CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births
UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials
Approximately 125 million people worldwide are affected by some form of psoriasis
UCB’s Bimzelx granted FDA approval to treat hidradenitis suppurativa in adults
The inflammatory skin disease affects approximately one in every 100 people in the US
UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab
The drug showed benefits across key secondary endpoints, including tau accumulation
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
The inflammatory skin disease affects about 1% of the population in most studied countries
Acelyrin shares positive phase 3 results for izokibep in hidradenitis suppurativa
Despite the promising readout, the company said it will not be moving forward with the candidate in the inflammatory skin condition